ArticleFundamental research2025
Carrier-free delivery of nucleic acid and photosensitizer nanoparticles for enhanced photodynamic and gene antitumour therapy.
Article in Fundamental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Cancer Drug Delivery with Nanoparticles and Biomolecules: Stimuli-Responsive, Theranostic, and AI-Guided Approaches.Materials (Basel, Switzerland) · 2026Review
- Augmented therapeutic efficacy of Erianin through pH-responsive charge-reversal liposome integrated synergistic PTT and PDT in breast cancer.Journal of pharmaceutical analysis · 2026Article
- Epithelial thickness as a new predictor of recurrence in oral leukoplakia after photodynamic therapy: a retrospective cohort study.BMC oral health · 2026Article
- NIR-triggered programmable nanomotor with HMaterials today. Bio · 2025Article
- NIR-Triggered siRNA Release and Lysosomal Escape for Synergistic Photothermal Tumor Therapy.International journal of nanomedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activated anti-oxidation reactions in cells partially diminish the anticancer effect of photodynamic therapy (PDT), significantly hindering efforts to increase the efficacy of PDT. The expression of transcription factor E2 related factor 2 (Nrf2), an important redox-regulated transcription factor, can be downregulated by Nrf2 siRNA, leading to greatly enhanced PDT effects. However, the efficient co-delivery of photosensitizers and siRNAs remains a key problem because these agents are complex to synthesize, exhibit poor biocompatibility and load drugs with a low efficiency. Herein, we designed a carrier-free and extremely simple strategy to co-deliver a photosensitizer and Nrf2 siRNA to cancer cells. In this nanoplatform, an indocyanine green photosensitizer, siRNA and FeⅡ were self-assembled to form a spherical hybrid structure with a uniform size, high loading ratio and adjustable component ratio. The platform can effectively transfer photosensitizers and siRNAs into cells and effectively inhibit tumour growth
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.